A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy.

Clicks: 385
ID: 11590
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #7 of 23 articles by views in nanomedicine (london, england)

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Biomarker-targeted nanocarrier holds promise for early diagnosis and effective therapy of cancer. This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer and . Blood biochemical and histological analyses show that the toxicity of GPC1-GEM-nanoparticles (NPs) was negligible. Both and studies demonstrate that GPC1-GEM-NPs can be used as NIRF/MR contrast agent for pancreatic cancer detection. Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls. This novel theranostic nanoplatform provides early diagnostic and effective therapeutic potential for pancreatic cancer.
Reference Key
qiu2019ananomedicine Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Qiu, Wenli;Zhang, Huifeng;Chen, Xiao;Song, Lina;Cui, Wenjing;Ren, Shuai;Wang, Yajie;Guo, Kai;Li, Donghui;Chen, Rong;Wang, Zhongqiu;
Journal nanomedicine (london, england)
Year 2019
DOI
10.2217/nnm-2019-0063
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.